FDA Clearance Tracker · K243500
ARCHITECT iGentamicin
Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jul 9, 2025
Substantially Equivalent
Time to decision
239 days
Received Nov 12, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K243500
- Device name
- ARCHITECT iGentamicin
- Applicant
- Abbott Laboratories
- Applicant location
- Abbott Park, IL
- Received
- Nov 12, 2024
- Decided
- Jul 9, 2025
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Enzyme Immunoassay, Gentamicin (LCD)
- Device class
- Class II
- Regulation
- 21 CFR 862.3450
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LCD. The earliest in FDA's data is K800150, decided Feb 5, 1980.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K243500
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- Anti-HCV Next510(k)
K252424 · Decided Apr 28, 2026 · 270 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- Alinity i Rubella IgG510(k)
K243168 · Decided Jun 20, 2025 · 263 days after receipt
Device type: Enzyme Linked Immunoabsorbent Assay, Rubella (LFX) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.